Blog
RSS FeedPosted by Michael Wonder on 21 Mar 2022
EMA publishes agenda for 21-24 March CHMP meeting
21 March 2022 - The EMA has published a draft agenda for this week's CHMP meeting. ...
Posted by Michael Wonder on 21 Mar 2022
ATAGI update following weekly COVID-19 meeting (16 March 2022)
21 March 2022 - An update from the Australian Technical Advisory Group on Immunisation (ATAGI) following their weekly meeting on 16 ...
Posted by Michael Wonder on 20 Mar 2022
AbbVie expands immunology portfolio in Canada as Health Canada approves Skyrizi (risankizumab) for the treatment of adults with active psoriatic arthritis
17 March 2022 - Approval supported by data from two Phase 3 studies evaluating Skyrizi in psoriatic arthritis patients, KEEPsAKE-1 ...
Posted by Michael Wonder on 20 Mar 2022
U.S. Food and Drug Administration approves first LAG-3 blocking antibody combination, Opdualag (nivolumab and relatlimab-rmbw), as treatment for patients with unresectable or metastatic melanoma
18 March 2022 - Opdualag is a first in class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and ...
Posted by Michael Wonder on 19 Mar 2022
Heron Therapeutics announces approval of Zynrelef by Health Canada for the management of post-operative pain
17 March 2022 - ZYNRELEF is the first and only extended-release local anaesthetic approved by Health Canada. ...
Posted by Michael Wonder on 18 Mar 2022
Moderna submits amendment to the emergency use authorisation for an additional booster dose of its COVID-19 vaccine in the U.S.
17 March 2022 - Moderna today announced that it has submitted a request to the U.S. FDA for an amendment ...
Posted by Michael Wonder on 18 Mar 2022
Marinus Pharmaceuticals announces FDA approval of Ztalmy (ganaxolone) for CDKL5 deficiency disorder
18 March 2022 - Rare paediatric disease priority review voucher awarded to Marinus Pharmaceuticals by the FDA. ...
Posted by Michael Wonder on 18 Mar 2022
Australian cancer patients to get improved access to clinical trials
17 March 2022 - Australian cancer patients will get improved access to local clinical trials through a new public-private partnership ...
Posted by Michael Wonder on 17 Mar 2022
Health Canada authorises Moderna's COVID-19 vaccine in children (6-11 years)
17 March 2022 - Announcement follows recent authorisation of the Company's mRNA COVID-19 vaccine in Australia and the European Union ...
Posted by Michael Wonder on 17 Mar 2022
Panel scrutinises quick FDA drug approvals
17 March 2022 - A House committee will spotlight an FDA process that’s been criticised as putting some of the ...
Posted by Michael Wonder on 17 Mar 2022
Backing life-saving local cancer drug development
17 March 2022 - Joint media release with the Minister for Health and Aged Care the Hon Greg Hunt MP. ...
Posted by Michael Wonder on 17 Mar 2022
U.S. FDA approves FoundationOne CDx as a companion diagnostic for EGFR therapeutics targeting exon 19 deletions or exon 21 substitutions in non-small cell lung cancer
17 March 2022 - Foundation Medicine’s tissue-based test is the first and only comprehensive genomic profiling test to be approved ...
Posted by Michael Wonder on 17 Mar 2022
Aquestive Therapeutics receives FDA fast track designation for AQST-109 for emergency treatment of allergic reactions including anaphylaxis
17 March 2022 - Aquestive Therapeutics today announced that the U.S. FDA has granted fast track designation to AQST-109, the first ...
Posted by Michael Wonder on 17 Mar 2022
COVID-19 vaccine weekly safety report (17 March 2022)
17 March 2022 - To 13 March 2022, the TGA has received 457 reports which have been assessed as likely to ...
Posted by Michael Wonder on 16 Mar 2022
Rinvoq (upadacitinib) receives FDA approval for the treatment of adults with moderately to severely active ulcerative colitis
16 March 2022 - In clinical trials, Rinvoq (upadacitinib) achieved the primary endpoints of clinical remission (per modified Mayo Score) at ...